RJA
RYTM icon

Raymond James & Associates’s Rhythm Pharmaceuticals RYTM Stock Holding History

Raymond James & Associates’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-22,600
Closed -$554K – 4048
2022
Q3 		$554K Buy
+22,600
New +$420K ﹤0.01% 2792

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Raymond James & Associates's RYTM Position: Q4 2022 in Review

Raymond James & Associates sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2022, closing a stake of 22,600 shares — an estimated $554K sold.

Raymond James & Associates first reported a position in RYTM in Q3 2022 and held it in 1 quarter. The position peaked at $554K in Q3 2022. 115 funds tracked by Wall St. Rank hold RYTM as of Q4 2022.

  • Raymond James & Associates reported no remaining Rhythm Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 22,600 Rhythm Pharmaceuticals shares in Q4 2022, an estimated $554K.
  • Raymond James & Associates first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Raymond James & Associates's Rhythm Pharmaceuticals position peaked at $554K in Q3 2022.
  • 115 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.